This company listing is no longer active
Provention Bio Balance Sheet Health
Financial Health criteria checks 5/6
Provention Bio has a total shareholder equity of $121.8M and total debt of $23.5M, which brings its debt-to-equity ratio to 19.3%. Its total assets and total liabilities are $236.9M and $115.0M respectively.
Key information
19.3%
Debt to equity ratio
US$23.47m
Debt
Interest coverage ratio | n/a |
Cash | US$165.00m |
Equity | US$121.85m |
Total liabilities | US$115.01m |
Total assets | US$236.86m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 2VB's short term assets ($174.6M) exceed its short term liabilities ($90.4M).
Long Term Liabilities: 2VB's short term assets ($174.6M) exceed its long term liabilities ($24.6M).
Debt to Equity History and Analysis
Debt Level: 2VB has more cash than its total debt.
Reducing Debt: 2VB's debt to equity ratio has increased from 0% to 19.3% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 2VB has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 2VB is forecast to have sufficient cash runway for 10 months based on free cash flow estimates, but has since raised additional capital.